Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2021-05-31 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2021-05-31 English
Interim financial statements/report – English.pdf
Regulatory Filings
2021-05-31 English
Annual MD&A (amended) - English.pdf
Regulatory Filings
2021-05-28 English
Audited annual financial statements (amended) - English.pdf
Regulatory Filings
2021-05-28 English
52-109F1R - Certification of refiled annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the CEO of Pharmadrug Inc. regarding the refiled annual financial statements and annual Management's Discussion and Analysis (MD&A) for the year ended December 31, 2020. It is a certification form (Form 52-109F1R) confirming the review and fair presentation of the annual filings. The document does not contain the actual financial statements or MD&A but certifies their accuracy and completeness. It is primarily an officer certification related to annual filings, which according to the rules, should be classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K) itself. The document length is short (3265 characters), and it is a certification rather than the report itself.
2021-05-28 English
52-109F1R - Certification of refiled annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the Chief Financial Officer regarding the refiled annual financial statements and Management's Discussion and Analysis for the year ended December 31, 2020. It is a certification under National Instrument 52-109, specifically a Venture Issuer Basic Certificate. The document does not contain the actual financial statements or detailed financial data but rather attests to the accuracy and fair presentation of the filings. According to the Certification Rule, such officer certifications or attestations, even if referencing annual filings, should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Discussion and Analysis (MDA). The document length is short (3259 characters), and it is primarily a certification letter, not the report itself.
2021-05-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.